That is, POLRMT inhibitors target tumors with high oxygen metabolism in the MDR or relapsed population, while conventional drugs such as cisplatin and docetaxel, i.e., target tumor cells that are highly proliferative or glycolysis-dependent. Here, POLRMT is linked to neoplasm.